Targeting TGF-β as a Marker and Pharmacological Target against Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 15 July 2024 | Viewed by 128
Special Issue Editor
Interests: molecular cancer biochemistry; mechanisms of tumor transformation and metastasis; epithelial–mesenchymal transition (EMT); oxidative stress and cancer; cancer and tumor microenvironment (TME); research of predictive markers and/or pharmacological targets in cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It is known that Transforming Growth Factor-β (TGF-β) plays a crucial role in carcinogenesis, and its alteration has been associated to cancer development and/or invasiveness, depending on the cancer stage. TGF-β acts as a driver of tumor progression and metastasis, via some alterations in TGF-β signaling pathway and some molecular events associated to malignant progression, such as epithelial–mesenchymal transition (EMT), angiogenesis, inhibition of the immune response and various aspects concerning the tumor microenvironment (TME). Thus, TGF-β signature may be considered a predictive marker in improving tumor diagnosis/prognosis, and TGF-β inhibition has been demonstrated to reduce tumor growth and prevent cancer metastasis.
Based on these considerations, this Special Issue will focus on identifying TGF-β, and its related targets in the signaling pathway, as significant and crucial for improving the preventive and therapeutic approach to cancer.
Therefore, in this Special Issue, original research articles and reviews are welcome. So, I am pleased to invite you to contribute to this Special Issue, with the aim of clarifying and deepening current knowledge, and for proposing further new research perspectives in the field of cancer at the molecular level.
I look forward to receiving your contributions.
Dr. Elisabetta Aldieri
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TGF-β
- cancer
- tumorigenesis
- metastasis
- epithelial–mesenchymal transition (EMT)
- marker
- therapy
